Xolair 300 MG/2 ML syringe 2ML
Ended Awarded
- Contract number
- SPE2DB26FNMNF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,605
Award facts
- Contract value 100% obligated
- $18,604.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,604.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The delivery order, issued on November 3, 2025, with an ultimate completion date of November 25, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's newly awarded Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.999 billion acquisition strategy established to support recurring medical supply needs of Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical supply chain, with substantial recent contracting activity from the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses a comprehensive range of pharmaceuticals including biologics, specialty medications, vaccines, and medical consumables, with the Xolair biologic agent representing one of numerous specialty pharmaceutical products the contractor supplies to support DoD healthcare operations. The PPV-G GEN V contract framework, structured with a 30-month base period and three 30-month option periods extending through December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FNMNF?
SPE2DB26FNMNF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DB26FNMNF worth?
The government has obligated $18,605 on SPE2DB26FNMNF.
Is contract SPE2DB26FNMNF an order under another contract?
Yes. SPE2DB26FNMNF is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNF competed?
The extent of competition for SPE2DB26FNMNF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award